AAAAAA

   
Results: 1-18 |
Results: 18
Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12
Authors: Gollob, JA Veenstra, KG Mier, JW Atkins, MB
Citation: Ja. Gollob et al., Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12, J IMMUNOTH, 24(1), 2001, pp. 91-98
Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials
Authors: Atkins, MB Dutcher, J Weiss, G Margolin, K Clark, J Sosman, J Logan, T Aronson, F Mier, J
Citation: Mb. Atkins et al., Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials, MED ONCOL, 18(3), 2001, pp. 197-207
Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines
Authors: Dutcher, J Atkins, MB Margolin, K Weiss, G Clark, J Sosman, J Logan, T Aronson, F Mier, J
Citation: J. Dutcher et al., Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines, MED ONCOL, 18(3), 2001, pp. 209-219
Patient preferences for adjuvant interferon alfa-2b treatment
Authors: Kilbridge, KL Weeks, JC Sober, AJ Haluska, FG Slingluff, CL Atkins, MB Sock, DE Kirkwood, JM Nease, RF
Citation: Kl. Kilbridge et al., Patient preferences for adjuvant interferon alfa-2b treatment, J CL ONCOL, 19(3), 2001, pp. 812-823
Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system
Authors: Balch, CM Soong, SJ Gershenwald, JE Thompson, JF Reintgen, DS Cascinelli, N Urist, M McMasters, KM Ross, MI Kirkwood, JM Atkins, MB Thompson, JA Coit, DG Byrd, D Desmond, R Zhang, YT Liu, PY Lyman, GH Morabito, A
Citation: Cm. Balch et al., Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system, J CL ONCOL, 19(16), 2001, pp. 3622-3634
Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma
Authors: Balch, CM Buzaid, AC Soong, SJ Atkins, MB Cascinelli, N Coit, DG Fleming, ID Gershenwald, JE Houghton, A Kirkwood, JM McMasters, KM Mihm, MF Morton, DL Reintgen, DS Ross, MI Sober, A Thompson, JA Thompson, JF
Citation: Cm. Balch et al., Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma, J CL ONCOL, 19(16), 2001, pp. 3635-3648
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Authors: Kaser, A Brandacher, G Steurer, W Kaser, S Offner, FA Zoller, H Theurl, I Widder, W Molnar, C Ludwiczek, O Atkins, MB Mier, JW Tilg, H
Citation: A. Kaser et al., Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis, BLOOD, 98(9), 2001, pp. 2720-2725
Interleukin-2 in metastatic melanoma: What is the current role?
Authors: Atkins, MB
Citation: Mb. Atkins, Interleukin-2 in metastatic melanoma: What is the current role?, CA J SCI AM, 6, 2000, pp. S8-S10
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
Authors: Atkins, MB Kunkel, L Sznol, M Rosenberg, SA
Citation: Mb. Atkins et al., High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update, CA J SCI AM, 6, 2000, pp. S11-S14
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
Authors: McDermott, DF Mier, JW Lawrence, DP van den Brink, MRM Clancy, MA Rubin, KM Atkins, MB
Citation: Df. Mcdermott et al., A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma, CLIN CANC R, 6(6), 2000, pp. 2201-2208
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
Authors: Gollob, JA Mier, JW Veenstra, K McDermott, DF Clancy, D Clancy, M Atkins, MB
Citation: Ja. Gollob et al., Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response, CLIN CANC R, 6(5), 2000, pp. 1678-1692
A new American Joint Committee on Cancer staging system for cutaneous melanoma
Authors: Balch, CM Buzaid, AC Atkins, MB Cascinelli, N Coit, DG Fleming, ID Houghton, A Kirkwood, JM Mihm, MF Morton, DL Reintgen, D Ross, MI Sober, A Soong, SJ Thompson, JA Thompson, JF Gershenwald, JE McMasters, KM
Citation: Cm. Balch et al., A new American Joint Committee on Cancer staging system for cutaneous melanoma, CANCER, 88(6), 2000, pp. 1484-1491
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy
Authors: Vannier, E Kaser, A Atkins, MB Fantuzzi, G Dinarello, CA Mier, JW Tilg, H
Citation: E. Vannier et al., Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy, EUR CYTOKIN, 10(1), 1999, pp. 37-41
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer
Authors: Robertson, MJ Cameron, C Atkins, MB Gordon, MS Lotze, MT Sherman, ML Ritz, J
Citation: Mj. Robertson et al., Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer, CLIN CANC R, 5(1), 1999, pp. 9-16
Conventional dose melphalan is inactive in metastatic melanoma: results ofan Eastern Cooperative Oncology Group Study (E1687)
Authors: Hochster, H Strawderman, MH Harris, JE Atkins, MB Oken, M Skeel, RT Jubelirer, SJ Parkinson, D
Citation: H. Hochster et al., Conventional dose melphalan is inactive in metastatic melanoma: results ofan Eastern Cooperative Oncology Group Study (E1687), ANTI-CANC D, 10(2), 1999, pp. 245-248
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
Authors: Atkins, MB Lotze, MT Dutcher, JP Fisher, RI Weiss, G Margolin, K Abrams, J Sznol, M Parkinson, D Hawkins, M Paradise, C Kunkel, L Rosenberg, SA
Citation: Mb. Atkins et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993, J CL ONCOL, 17(7), 1999, pp. 2105-2116
Liver metastases from melanoma: Detection with multiphasic contrast-enhanced CT
Authors: Blake, SP Weisinger, K Atkins, MB Raptopoulos, V
Citation: Sp. Blake et al., Liver metastases from melanoma: Detection with multiphasic contrast-enhanced CT, RADIOLOGY, 213(1), 1999, pp. 92-96
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
Authors: Alpaugh, RK von Mehren, M Palazzo, I Atkins, MB Sparano, JA Schuchter, L Weiner, LM Dutcher, JP
Citation: Rk. Alpaugh et al., Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon, MED ONCOL, 15(3), 1998, pp. 191-198
Risultati: 1-18 |